MarketStudyReport.com Adds New “Global Cancer Diagnostics Market research report for the period of 2017 – 2024 to its research database covering information and data by application, by cancer type, by end-use, industry analysis report, regional outlook, application potential, price trends, competitive market share & forecast spreading across 250 Pages with table and figures in it.
Cancer Diagnostics Market is set to exceed USD 156 billion by 2024; according to a new research report.
Increasing prevalence of cancer across the globe will be major driving factor for cancer diagnostics market. World Health Organization reported that cancer accounted for 8.8 million deaths in 2015 and was second leading cause of mortality. Unhealthy eating habits and changing lifestyle are further expected to boost prevalence in near future rendering significant positive impact on demand for better cancer diagnostic methods.
Increasing government initiatives to spread awareness pertaining to benefits of early diagnosis will boost cancer diagnostics market growth over the forecast timeframe. Awareness and accessibility of cancer diagnostic products is lower in developing and underdeveloped regions. Private as well as government organizations are conducting awareness campaigns to educate people regarding the importance of early diagnosis. Such activities will influence industrial growth. For instance, Roche in partnership with China Cancer Rehabilitation Society (CCRS) conducted ‘Run for Her' campaign to raise awareness about mammography.
Get Sample Copy of This Research Report: https://www.marketstudyreport.com/request-a-sample/859978/?utm_source=TUBML-AN
Recent technological advancements enabling quick and accurate diagnosis will propel cancer diagnostics market growth. Patients are receiving treatment specifically tailored with accordance to their genetic makeup with the help of diagnosis based of next generation sequencing and liquid biopsy. Advent of such technologies in near future will support industry growth.
U.S. dominated cancer diagnostics market in 2016, due to high research and development activities focused at developing better diagnostic methods. Presence of leading medical technology and biotechnology firms coupled with high adoption rates of technologically superior diagnostic methods will drive the U.S. cancer diagnostics market growth over the forecast timeframe.
The liver-lung cancer application segment accounted for majority of market share in 2016. The segment growth is largely supported by increasing prevalence due to changing dietary habits such as increasing alcohol consumption and smoking.
Purchase this report at: https://www.marketstudyreport.com/securecheckout/paymenta/859978?msfpaycode=sumsf?utm_source=TUMBL-AN
However, prohibitive cost of diagnosis is hampering adoption rates in countries with low income levels. Risk of radiations exposure will further impede market growth over the forecast period.
Imaging application segment held largest revenue share in 2016 and the trend is expected to continue over the forecast timeframe owing to wide range of applicability of imaging devices to detect majority of cancer types. Advent of technologically advanced devices such as computed tomography and positron emission tomography devices will positively impact market growth. These devices provide high quality imaging at lower radiation dose. The side effects associated with usage of some conventional imaging devices due to radiation exposure will hinder segment growth to some extent.
China cancer diagnostic market should witness robust growth due to presence of large patient pool and increasing disposable income. Growing awareness pertaining to benefits of early diagnosis will propel market growth. However, being a price sensitive market, inflated cost of some advanced diagnostic tests may limit regional growth to some extent.
Some of the key industry players operating in global cancer diagnostics market are Sienna Cancer Diagnostics, F. Hoffmann-La Roche, Becton, Dickinson and Company, C.R. Bard, Qiagen, Abbott Laboratories, Hoffmann-La Roche, Thermo Fisher Scientific, Siemens AG, Bio Rad Laboratories, GE Healthcare, Illumina, Koninklijke Philips, Toshiba Medical Systems Corporation, Agilent Technologies, and Hologic. Industry players are trying to garner higher market share through various organic as well as inorganic growth strategies. The companies in the industry are further trying to develop cost-effective and accurate diagnostics methods to get a competitive edge.
· Chapter 2. Executive Summary
· Chapter 3. Cancer Diagnostics Industry Insights
· Chapter 4. Cancer Diagnostics Market, By Application
· Chapter 5. Cancer Diagnostics Market, By Cancer type
· Chapter 6. Cancer Diagnostics Market, By End-use
· Chapter 7. Cancer Diagnostics Market, By Region
· Chapter 8. Company Profiles
Global Peptide Cancer Vaccine Market 2018 Forecast to 2023
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
This report focuses on the Peptide Cancer Vaccine in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
https://www.marketstudyreport.com/reports/global-north-america-europe-and-asia-pacific-south-america-middle-east-and-africa-peptide-cancer-vaccine-market-2018-forecast-to-2023/?utm_source=RR-AN
About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.
US Toll Free: 1-866-764-2150
Website:https://www.marketstudyreport.com
https://www.marketstudyreport.com/category/news-releases/
